Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

SPA agreement for pivotal study of oral Fodosine in cutaneous T-cell lymphoma

July 10, 2007

Hsp32 validated as a therapeutic target in systemic mastocytosis

July 10, 2007

Clavis Pharma's phase II combination study of Elacyt approved

July 10, 2007

BHI-001: a novel Hsp90 inhibitor with improved therapeutic index

July 10, 2007

New therapeutics for cancer covered in recent patent literature

July 10, 2007

SuperGen reports dosing of first patient in phase I trial of novel TKI

July 9, 2007

Biomira files IND for phase I trial of HIF-1 alpha inhibitor PX-478

July 6, 2007

Algeta enters new collaboration to expand TH-1 targeted cancer therapy program

July 6, 2007

EpiCept accelerates clinical trials of EPC-2407 in cancer

July 5, 2007

Algeta initiates clinical dosimetry study with Alpharadin in HRPC patients

July 5, 2007

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...